J&J down­sizes in­fec­tious dis­ease and vac­cine pipeline, cut­ting he­pati­tis B pro­grams

John­son & John­son has culled sev­en pro­grams from its in­fec­tious dis­ease pipeline since the first quar­ter of the year, most of which are he­pati­tis B ther­a­pies, as part of a “pri­or­i­ti­za­tion” of its R&D busi­ness.

In the Big Phar­ma’s sec­ond quar­ter earn­ings re­port on Thurs­day, its pipeline no longer in­cludes ex­per­i­men­tal treat­ments for he­pati­tis B and D, flu, and some HIV can­di­dates.

J&J had been test­ing JNJ-3989, a com­bo ther­a­py for he­pati­tis B and a he­pati­tis B and D co-in­fec­tion in Phase II tri­als. JNJ-7744 and JNJ-3283 were both in Phase I for he­pati­tis B, while JNJ-0953 was in Phase II for in­fluen­za.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER